CLXPF News and Press, Canadian Lynx Pete Ltd From 05/20/21

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, has filed a provisional patent application in support of its ongoing drug candidate programs. The patent is the 12th patent filed by the company. In the announcement, the company note...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed a new provisional patent application in support of its ongoing dru...

While medical science is still working to establish how different cannabinoids can best be used to combat widespread/systemic inflammation, psychedelics researchers are hard at work to develop a “ wonder drug ” for systemic inflammation from psychedelics. An LSU Health Scienc...

NetworkNewsWire Editorial Coverage : Before 1970, promising research was being conducted on the potential therapeutic effects of a broad category of psychedelic drug compounds, including substances such as psilocybin, DMT (dimethyltryptamine), LSD (lysergic acid diethylamide) and MDMA (meth...

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the Institutional Review Board (“IRB”) at the University of the West Indies Hospital, in Jamaica has granted approval to commence the stud...

A bill that was recently introduced in Maine will legalize psilocybin’s therapeutic use and establish a licensed industry for the drug. Psilocybin is the main active compound found in magic mushrooms. Introduced by State Sen. Donna Bailey, the Maine Psilocybin Services Act will ...

April analyst reports all point to a bright future for Cybin “CYBN is a true multi-molecule company that's not being reflected in its valuation,” reports Stifel “With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently acquired Adelia Therapeutics, thereby adding CYB003 to its pipeline. It subsequently made an equally important move when it inked a dru...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 13, 2021 – Psychedelics are quietly being used in clinical settings on small numbers of patients, but they are moving quickly toward medical approval. The FDA recently approved large...

Since selective serotonin reuptake inhibitor antidepressants (“SSRIs”) were introduced in the late ‘80s, little has changed in how different mental health conditions are treated. The co-founder of the Institute for Integrative Therapies (“IIT”) Manoj ...